Studies on post-transplant dyslipidemia in kidney transplant patients

Hiroshima Journal of Medical Sciences

Volumn 54, Issue 2, 2005, Pages 39-45

  Marubayashi, Seiji ^a   Ohdan, Hideki ^b   Tashiro, Hirotaka ^b   Tokita, Daisuke ^b   Onoe, Takashi ^b   Hayamizu, Keisuke ^b   Asahara, Toshimasa ^b   Doi, Shigehiro ^a   Okumoto, Satoshi ^a   Tanji, Chie ^a   Kawai, Tohru ^a   Taniguchi, Yoshihiko ^a   Fukuda, Yasuhiko ^c   Dohi, Kiyohiko ^d  

^a HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c HIROSHIMA PREFECTURAL HOSPITAL   (Japan)

^d Chugoku Rousai Hospital   (Japan)

Author keywords

Cyclosporine A; Dyslipidemia; Immunosuppressant; Renal transplantation; Steroids

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CHOLESTEROL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HLA DR ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MALE; OUTCOMES RESEARCH; PATIENT SELECTION; RECIPIENT; RETROSPECTIVE STUDY; STEROID THERAPY; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; CHOLESTEROL; CHOLESTEROL, HDL; CYCLOSPORINE; FEMALE; HUMANS; HYPERLIPIDEMIAS; KIDNEY TRANSPLANTATION; MALE; METHYLPREDNISOLONE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 21744448647     PISSN: 00182052     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Abou-Jaoude, M.M. and Almawi, W.Y. 2003. Single-center experience with tacrolimus-based immunosuppressive regimens in renal transplantation. Mol. Immunol. 39: 1067-1072.
2. Fellstrom, B., Holdaas, H., Jardine, A.G., Holme, I., Nyberg, G., Fauchald, P., Gronhagen-Riska, C.M., Madsen, S., Neumayer, H.H., Cole, E., Maes, B., Ambuhl, P., Olsson, A.G., Hartmann, A., Logan, J.O. and Pedersen, T.R. 2004. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney Int. 66: 1549-1555.
3. Fernandez-Miranda, C., De la Calle, A., Morales, J.M., Guijarro, C., Aranda, J.L., Gomez-Sanz, R., Gomez-Izquierdo, T., Larumbe, S., Moreno, E., Rodicio, J.L. and Del Palacio, A. 1998. Lipoprotein abnormalities in long-term stable liver and renal transplanted patients. A comparative study. Clin. Transplant 12: 136-141.
4. Hanefeld, M., Fischer, S., Julius, U., Schulze, J., Schwanebeck, U., Schnechel, H., Ziegelasch, H.J. and Lindner, J. 1996. Risk factors for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11-year follow-up. Diabetologia 36: 1577-1583.
5. Jensik, S.C. 1998. Tacrolimus (FK506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. The FK506 Kidney Transplant Study Group. Transplant. Proc. 30: 1216-1218.
6. Kahan, B.D. 1989. Cyclosporine. N. Engl. J. Med. 321: 1725-1738.
7. Kasiske, B.L. and Umen, A.J. 1987. Persistent hyperlipidemia in renal transplant patients. Medicine 66: 309-315.
8. Kasiske, B.L., Tortorice, K.L., Heim-Duthoy, K.L., Awni, W.M. and Rao, K.V. 1991. The adverse impact of cyclosporine on serum lipids in renal transplant recipients. Am. J. Kidney Dis. 17: 700-707.
9. Kasiske, B., Cosio, F.G., Beto, J., Bolton, K., Chavers, B.M., Grim, Jr. R., Levin, A., Masri, B., Parekh, R., Wanner, C., Wheeler, D.C. and Wilson, P.W.F. 2004. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: report from the managing dyslipidemias in chronic kidney disease work group of the national kidney foundation kidney disease outcomes initiative. Am. J. Transplant. 4 (Suppl. 7): 13-53.
10. Keane, W.F. 1994. Lipids and the kidney. Kidney Int. 46: 910-920.
11. Marubayashi, S., Tashiro, H., Ohdan, H., Tokita, D., Hara, H., Onoe, T., Kitayama, T., Hayamizu, K., Asahara, T., Doi, M., Okumoto, S., Taniguchi, T., Fukuda, Y. and Dohi, K. 2004. Studies on eleven kidney transplants from non-heart-beating donors. Hiroshima J. Med. Sci. 53: 7-11.
12. Massy, Z.A. and Kasiske, B.L. 1996. Post-transplant hyperlipidemia: Mechanisms and management. J. Am. Soc. Nephrol. 7: 971-977.
13. Raine, A.E., Carter, R., Mann, J.I. and Morris, P.J. 1988. Adverse effect of cyclosporine on plasma cholesterol in renal transplant recipients. Nephrol. Dial. Transplant. 3: 458-463.
14. Sutherland, F., Burgess, E., Klassen, J., Buckle, S. and Paul, L.C. 1993. Post-transplant conversion from cyclosporin to azathioprine: effect on cardiovascular risk profile. Transplant. Int. 6: 129-132.
15. Thompson, C.R.V. 2001. Cardiovascular complications after renal transplantation, pp. 445-467. In P. J. Morris (ed.), Kidney Transplantation, 5th ed, W.B. Saunders Comp., Philadelphia.
16. Wissing, K.M., Abramowicz, D., Broeders, N. and Vereer-straeten, P. 2000. Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection. Transplantation 70: 464-472.
17. Wlodarczyk, Z., Walaszewski, J., Perner, F., Vitko, S., Ostrowski, M., Bachleda, P., Kokot, F., Klinger, M., Szenohradszky, P., Studenik, P., Navratil, P., Asztalos, L., Rutkowski, B., Kalmar, K.N. and Hickey, D. 2005. Steroid withdrawal at 3 months after kidney transplantation: a comparison of two tacrolimus-based regimens. Transplant. Int. 18: 157-162.
18. Woodle, E.S., Vincenti, F., Lorber, M.I., Gritsch, H.A., Hricik, D., Washburn, K., Matas, A.J., Gallichio, M. and Neylan, J. 2005. A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus. Am. J. Transplant. 5: 157-166.